相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa et al.
CANCER SCIENCE (2010)
Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan
Yousuke Nakai et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Atsuko Soeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer
Yoshiki Hirooka et al.
PANCREAS (2009)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Gemcitabine as significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects
Eiji Suzuki et al.
CANCER BIOLOGY & THERAPY (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer
Hiroaki Yanagimoto et al.
CANCER SCIENCE (2007)
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
C. Bauer et al.
GUT (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Regulatory T cells and Toll-like receptors in cancer therapy
Rong-Fu Wang
CANCER RESEARCH (2006)
Antitumor effect of OK-432-derived DNA - One of the active constituents of OK-432, a streptococcal immunotheropeutic agent
T Oshikawa et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers
Y. Oka et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling
M Okamoto et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
JMD Plate et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
H Sugiyama
EXPERT REVIEW OF VACCINES (2005)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
RK Ramanathan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Immunological treatment of ovarian cancer
MJ Cannon et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2004)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
M Okamoto et al.
CANCER RESEARCH (2004)
Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator - Involvement of Toll-like receptor 4
SU Ahmed et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses
S Sakaguchi
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
H Nagayama et al.
MELANOMA RESEARCH (2003)
Involvement of toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432
M Okamoto et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E-2
M Sato et al.
CANCER SCIENCE (2003)
Dendritic cells for NK/LAK activation:: rationale for multicellular immunotherapy in neuroblastoma patients
D Valteau-Couanet et al.
BLOOD (2002)
Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model
K Kontani et al.
CANCER GENE THERAPY (2002)
Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy
U Keilholz et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus
M Okamoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
Generation of T cells specific for the wild-type sequence p53264-272 peptide in cancer patients:: Implications for immunoselection of epitope loss variants
TK Hoffmann et al.
JOURNAL OF IMMUNOLOGY (2000)
Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred
P Mukherjee et al.
JOURNAL OF IMMUNOLOGY (2000)
Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients
M Okamoto et al.
ANTI-CANCER DRUGS (2000)
分享论文
